MET and non-small cell lung carcinoma: Tepotinib (trade name Tepmetko) is a novel c-MET tyrosine kinase inhibitor that was recently approved in Japan for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring a MET exon 14 skipping mutation [6].